Table 1.
Systolic blood pressure (SBP, mmHg), non-fasting plasma glucose (mg/dL), sodium (mEq/L), calcium (mg/dL), phosphate (mg/dL), tartrate-resistant acid phosphatase-5b (TRACP-5b, ng/ml), glomerular filtration rate (GFR, ml/min/100 mg. kidney weight), body weight (BW, g.), kidney weight (g.), kidney/body weight ratio (mg/g), in Control, Control + Empa, CSA-treated rats and CSA + Empagliflozin-treated rats at the end of the experimental period
| Control | Control + Empa | CsA | CsA + Empa | |
|---|---|---|---|---|
| SBP, mmHg | 139.9 ± 5.3 | 145.9 ± 1.6 | 166.6 ± 3.3†ε | 152.5 ± 3.1*δ |
| Plasma glucose, mg/dL | 133.2 ± 9.0 | 142.6 ± 3.5 | 149.5 ± 11.3 | 115.7 ± 6.9 δ |
| Plasma sodium, mEq/L | 141.8 ± 1.0 | 141.0 ± 0.8 | 143.2 ± 0.3 | 142.6 ± 0.8 |
| Plasma calcium, mg/dL | 5.42 ± 0.14 | 6.13 ± 0.49 | 7.16 ± 0.38† | 5.77 ± 0.34 δ |
| Plasma phosphate, mg/dL | 6.49 ± 0.12 | 6.23 ± 0.17 δ | 7.00 ± 0.33 | 5.70 ± 0.23 ζ |
| Plasma TRACP-5b, ng/ml | 0.669 ± 0.04 | 0.701 ± 0.01 | 0.854 ± 0.04* | 0.827 ± 0.06* |
| GFR, ml/min/100 mg.Kidney | 0.290 ± 0.02 | 0.243 ± 0.01 | 0.220 ± 0.01* | 0.253 ± 0.02 |
| BW, g | 405.8 ± 14.2 | 374.2 ± 6.2 | 398.3±9.6 | 348.5 ± 14.3† ζ |
| Kidney weight, g | 1.475 ± 0.03 | 1.635 ± 1.33 | 1.571 ± 0.07 | 1.583 ± 0.06 |
| Kidney/Body weight, mg/g | 3.647 ± 0.10 | 4.386 ± 0.41† | 3.938 ± 0.12 | 4.551 ± 0.10† δ |
* = p < 0.05 versus control; † = p < 0.01 versus control; δ = p < 0.05 versus CSA; ζ = p < 0.01 versus CSA; ε = p < 0.01 versus Control + Empa